A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Metastatic Well Differentiated Neuroendocrine Neoplasm
- Neuroendocrine Tumors
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 90 years
- Gender
- Both males and females
Description
Phase II, multicenter, open-label, non-comparative, non-randomized study with three-stage design
Phase II, multicenter, open-label, non-comparative, non-randomized study with three-stage design
Tracking Information
- NCT #
- NCT04427787
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Sara Pusceddu, MD Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Get Well Soon